---
title: "KHB: Net profit loss of 99.0801 million yuan in the third quarter, a decrease of 42.20%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263279124.md"
description: "KHB announced that its revenue for the third quarter was 398 million yuan, a year-on-year decrease of 9.96%; the net profit loss was 99.0801 million yuan, a decrease of 42.20%. The revenue for the first three quarters was 1.191 billion yuan, a year-on-year decrease of 11.77%; the net profit loss was 233 million yuan, a decrease of 90.38%"
datetime: "2025-10-29T11:43:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263279124.md)
  - [en](https://longbridge.com/en/news/263279124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263279124.md)
generator: "portal-rs"
---

# KHB: Net profit loss of 99.0801 million yuan in the third quarter, a decrease of 42.20%

KHB announced that its revenue for the third quarter was 398 million yuan, a year-on-year decrease of 9.96%; the net profit loss was 99.0801 million yuan, a decrease of 42.20%. Revenue for the first three quarters was 1.191 billion yuan, a year-on-year decrease of 11.77%; the net profit loss was 233 million yuan, a decrease of 90.38%

### Related Stocks

- [002022.CN](https://longbridge.com/en/quote/002022.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [JDC: Record growth in turnover and EBITDA, with strong outlook driven by new regulation and AI](https://longbridge.com/en/news/296247395.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [08:15 ETNow's the Time: Late Summer Is the Best Season For Homebuyers to Score a Deal in These U.S. Metros](https://longbridge.com/en/news/296616885.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**